Found Review: GLP-1 Compounding & Clinical Standards

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Found Review is a telehealth service connecting patients to GLP-1 medications through remote clinical evaluation. Unlike single-product platforms, Found offers multiple GLP-1 and GLP-1/GIP compounds, leveraging licensed compounding pharmacies to provide flexible dosing and formulation options tailored to individual clinical profiles.

For patients exploring GLP-1 options, understanding the difference between compounding standards, provider vetting, and personalization frameworks is critical. PlexusDx emphasizes precision-wellness by combining compounded medication options with genetic insight into peptide receptor pathways, supporting more informed clinical conversations with your provider.

How Compounding Standards Shape GLP-1 Access

Compounded GLP-1 medications are manufactured under USP 797 standards in licensed 503A pharmacies, meaning each batch undergoes sterility, potency, and purity testing. Found Review uses compounding to offer customized dosing schedules and multi-drug formulations not available through branded pharmaceuticals alone.

PlexusDx exclusively partners with licensed 503A compounding pharmacies—never 503B—ensuring direct oversight of ingredient sourcing and quality control. This distinction matters: 503A facilities must maintain state pharmacy licensure, while 503B outsourcing models operate under different regulatory pathways. Patients should verify their provider's pharmacy credentials before starting any compounded medication.

Clinical Pathways: Provider Assessment and Eligibility Frameworks

Both Found and PlexusDx require licensed provider evaluation before dispensing GLP-1 medications. Typical assessment includes medical history, BMI/weight status, metabolic markers (glucose, lipids), and medication interactions. Found's model emphasizes rapid virtual visits; PlexusDx adds optional genetic context through the Precision Peptide Genetic Test to support discussion of individual peptide receptor sensitivity.

The clinical decision framework differs between platforms. Found offers pre-configured medication bundles; PlexusDx enables granular selection—compounded semaglutide, tirzepatide, microdose GLP-1 protocol, or dual-compound GLP-Squared—based on genetic predispositions, comorbidity status, and provider preference.

Criterion	Found Review Approach	PlexusDx Approach
Provider Model	Telehealth-first; rapid assessment	Licensed provider consultation with optional genetic insight
Compounding Pharmacy	Licensed 503A facilities	Exclusive 503A partners; no 503B outsourcing
Personalization Tool	Symptom and medical history intake	Precision Peptide Genetic Test (GIPR, GLP1R, FTO, MC4R variants)
Medication Options	Pre-configured bundles	Compounded semaglutide, tirzepatide, microdose, GLP-Squared dual compound
Pricing Model	Subscription-based access	$129-$369/mo depending on formulation and dosing protocol
Genetic Predisposition Testing	Not offered	$99 add-on or $298 standalone; reveals peptide pathway sensitivities

Understanding Genetic Predispositions in Peptide Pathways

GLP-1 medications work by activating glucagon-like peptide-1 receptors on pancreatic, intestinal, and central nervous system cells. Individual genetic variation in GLP1R, GIPR, FTO, and MC4R genes may influence how a person's body responds to these compounds. PlexusDx's Precision Peptide Genetic Test identifies predispositions in these pathways, not exact medication response.

Knowing your genetic profile in these pathways can support a more informed conversation with your provider about formulation choice, dosing strategy, and potential side effect risk. For example, FTO rs9939609 variants correlate with variable satiety signaling; MC4R rs17782313 status may relate to appetite-regulation baseline. Your provider can weigh these predispositions alongside clinical assessment to guide compound selection.

Safety, Side Effects, and Who GLP-1 Compounding Is Right For

Compounded GLP-1 medications carry the same physiological effects as branded equivalents: nausea, constipation, and gastrointestinal discomfort in early weeks are common. Serious risks include pancreatitis (rare), thyroid concerns in predisposed individuals, and hypoglycemia if combined with insulin. Patients with personal or family history of medullary thyroid cancer are typically excluded from GLP-1 use.

GLP-1 compounding is appropriate for adults with obesity (BMI ≥30) or overweight (BMI ≥25) with weight-related comorbidities, under active provider supervision. Pregnant individuals, those with uncontrolled diabetes, or significant renal/hepatic impairment require careful provider evaluation. PlexusDx recommends discussing genetic findings and personalization options with your healthcare provider before initiating any GLP-1 compound to ensure alignment with your clinical profile and goals.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for how your body's peptide signaling pathways are structured genetically. Testing reveals predispositions in GLP1R, GIPR, FTO, and MC4R—four key genes in appetite, glucose, and metabolic regulation. This insight should be interpreted alongside clinical markers and your provider's assessment to inform compound and dose selection.

The genetic test does not predict exact GLP-1 medication response or guarantee outcomes. Instead, it identifies whether you carry genetic variants associated with variable satiety signaling, insulin secretion baseline, or appetite-center sensitivity. For patients considering compounded semaglutide, tirzepatide, or dual-compound GLP-Squared, genetic context may support a more nuanced discussion about why certain formulations or dosing protocols might align better with your physiology.

Understanding your genetic predispositions in peptide pathways—combined with clinical markers like fasting glucose, lipids, and weight-loss history—can support a more personalized conversation with your PlexusDx provider. This precision-wellness approach moves beyond one-size-fits-all access models, enabling tailored compound selection and monitoring protocols that reflect your individual metabolic and genetic landscape.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is Found Review, and how does it differ from other GLP-1 platforms?

Found Review is a telehealth platform offering GLP-1 medications through remote provider assessment and licensed compounding. It emphasizes rapid access and flexible dosing. PlexusDx offers similar compounded options but adds optional genetic predisposition testing to support personalized provider conversations.

Are compounded GLP-1 medications from Found or PlexusDx FDA-approved?

Compounded medications are not FDA-approved as branded drugs. However, they are manufactured in licensed 503A pharmacies under USP 797 sterility and potency standards. Your provider must evaluate medical appropriateness before dispensing any compounded medication.

Does PlexusDx's genetic test predict exactly how I'll respond to GLP-1?

No. The Precision Peptide Genetic Test identifies genetic predispositions in peptide pathways, not exact medication response. It reveals variants in GLP1R, GIPR, FTO, and MC4R that may inform your provider's compound and dosing choice. Clinical evaluation remains the foundation of safe, effective treatment.

What is the cost difference between Found and PlexusDx compounded options?

PlexusDx compounded semaglutide ranges $149/mo; tirzepatide $249/mo; GLP-Squared dual compound $249/mo. Found's pricing varies by plan and medication bundle. Genetic testing costs $99 as an add-on or $298 standalone through PlexusDx, supporting personalized provider discussions.

Who should not use GLP-1 compounding, and what side effects are most common?

GLP-1 is contraindicated in individuals with personal/family history of medullary thyroid cancer, pregnancy, or uncontrolled diabetes. Common early side effects include nausea and gastrointestinal discomfort. Serious but rare risks include pancreatitis. Your provider should assess individual safety before starting any GLP-1 compound.

Found Review: Clinical Criteria and Compounding Standards for GLP-1 Access